Pharmacology · Antiviral Pharmacology

Antiviral Resistance Principles

Quasispecies, fitness cost, testing methods, and cross-resistance patterns

Antiviral resistance is never induced by drug exposure — it is selected from pre-existing minority variants that already exist within the quasispecies because RNA-dependent RNA polymerase generates every possible single-nucleotide mutation many times each day; drugs eliminate drug-sensitive wild-type virus and allow resistant minority populations to expand into dominance, which is why the logical counter-strategy is simultaneous multi-drug therapy requiring two or three independent resistance mutations to occur simultaneously.
Fitness cost explains why some resistance mutations become global public health crises while others remain confined to treated patients: influenza S31N (adamantane resistance) spread from 2% to 96% global prevalence in a single season through natural transmission because it costs the virus almost nothing in replicative fitness; dolutegravir INSTI resistance mutations carry high fitness cost, which is why transmitted INSTI resistance remains near zero despite widespread dolutegravir use.
Genotypic resistance testing must be performed while the patient is still on the failing regimen — wild-type virus outcompetes resistant variants rapidly once drug selection pressure is removed, and resistance mutations can become undetectable within weeks of drug discontinuation; a genotype performed after stopping the failing regimen may appear drug-sensitive even when archived resistance mutations are present and will re-emerge when that drug is re-introduced.
The HSV/VZV cross-resistance map follows directly from mechanism: because acyclovir, valacyclovir, and penciclovir all require viral thymidine kinase (TK) for the first phosphorylation step, a single TK gene mutation simultaneously eliminates all three agents; foscarnet and cidofovir bypass TK entirely and retain activity, making foscarnet the obligate first choice and cidofovir the backup when DNA polymerase mutations additionally reduce foscarnet susceptibility.
Sofosbuvir's status as the pharmacological anchor of all modern HCV therapy rests on the fact that its primary resistance mutation (S282T in NS5B) causes such severe viral fitness loss that it has never been documented in clinical practice despite cell culture evidence of its existence — this is a case where fitness cost is so extreme that natural selection itself prevents clinical resistance emergence, making sofosbuvir uniquely durable among antiviral drugs.

Abbreviations: RdRp = RNA-dependent RNA polymerase · TK = thymidine kinase · RAS = resistance-associated substitution · IC50 = 50% inhibitory concentration · TAM = thymidine analogue mutation · NRTI = nucleoside reverse transcriptase inhibitor · NNRTI = non-nucleoside reverse transcriptase inhibitor · NGS = next-generation sequencing · INSTI = integrase strand transfer inhibitor

Core Principle — Viral Quasispecies

Fundamental Principle

Resistance Is Selected, Not Induced

RNA viruses use error-prone RdRp — mutation rate ~10−4 to 10−6 per nucleotide per replication cycle
HIV: ~10 billion virions produced per day → every possible single-point mutation generated many times daily within one patient
Resistant variants pre-exist before therapy as minority variants — drug pressure does not create them, it selects them
Drug eliminates wild-type virus → resistant minority expands to dominance; removing drug pressure allows wild-type to re-expand
Combination therapy rationale: simultaneous resistance to 2–3 mechanistically diverse agents requires multiple independent mutations — probability many orders of magnitude lower than any single mutation

Epidemiological Determinant

Fitness Cost — Patient Problem vs. Public Health Crisis

Low Fitness CostResistant strain replicates as efficiently as wild-type → spreads without drug pressure through natural transmission
Influenza S31N (adamantane resistance): swept from 2% to 96% global prevalence in one season without selection pressure
High Fitness CostResistant variant replicates poorly → outcompeted by wild-type when drug removed; rarely transmitted
DTG/BIC INSTI resistance mutations: high fitness cost → near-zero transmitted resistance despite widespread use
Fitness cost determines whether resistance stays at the patient level or becomes a public health emergency

Resistance Testing Methods

Sequence-Based

Genotypic Testing

Sequences viral gene regions to identify mutations at resistance-associated codons
Standard Sanger sequencing: detects mutations present in >20% of the viral population
Next-generation sequencing (NGS): detects minority variants at 1–5% frequency — more sensitive for archived or emerging resistance
Results interpreted against curated mutation databases (Stanford HIVdb, Rega, ANRS)
Perform while still on failing regimen — wild-type rapidly outcompetes resistant variants after drug stopped; resistance mutations may become undetectable within weeks of discontinuation

Cell Culture-Based

Phenotypic Testing

Directly measures IC50 of resistant virus vs. reference wild-type in cell culture — fold-change in susceptibility is the result
Most informative when novel mutation combinations make genotypic interpretation uncertain
Limitations: expensive, slow (2–3 weeks), requires live viral culture infrastructure
Virtual phenotype: computational prediction of phenotypic result from genotypic data using large paired databases — faster and cheaper, widely used as a surrogate

HIV Resistance — Class-Specific Patterns

Two Distinct Mechanisms

NRTIs

DiscriminationM184V/I (3TC/FTC): high-level resistance, partially restores TDF/ZDV susceptibility — often maintained strategically; K65R (TDF): TDF/TAF/ABC resistance
Excision (TAMs)M41L, D67N, K70R, L210W, T215F/Y — selected by ZDV; enhance pyrophosphorolysis to remove incorporated chain terminators; multiple TAMs = broad class cross-resistance
M184V and K65R are mutually antagonistic — K65R suppresses TAM pathway

Low Resistance Barrier

NNRTIs

Low barrier — single mutation confers high-level resistance to first-generation agents
K103N: efavirenz and nevirapine resistance; low fitness cost → transmitted in ~2–8% newly diagnosed U.S. patients
Rilpivirine: distinct resistance mutations (E138K, K101E); K103N does NOT confer rilpivirine resistance
Doravirine: distinct resistance profile — may retain activity after efavirenz failure in some cases

Generation-Dependent Barrier

INSTIs

First generation (RAL/EVG): low barrier — Y143, Q148, N155 mutations confer resistance; Q148+G140S reduces DTG susceptibility 8–25-fold
Second generation (DTG/BIC): very high barrier — no consistent single-mutation resistance pathway in treatment-naive patients
Transmitted INSTI resistance: rare (high fitness cost of relevant DTG/BIC resistance mutations)

Cross-Resistance — Herpesvirus and HCV

Mechanism-Derived Map

Herpesvirus Cross-Resistance

TK Mutation (Most Common)Acyclovir, valacyclovir, penciclovir, famciclovir all lose activity simultaneously — all require viral TK for first phosphorylation
Foscarnet and cidofovir retain activity — neither requires TK; foscarnet is obligate first choice
DNA Polymerase MutationMay reduce acyclovir AND foscarnet susceptibility (both target the polymerase); cidofovir may retain activity (different binding site)
Clinical rule: acyclovir-resistant HSV → foscarnet; foscarnet also fails → cidofovir only option

Clinical Relevance

HCV Resistance-Associated Substitutions

NS5A RASs (positions 28, 30, 31, 93)Clinically relevant for first-generation agents (ledipasvir, elbasvir); velpatasvir and pibrentasvir retain activity against most NS5A RASs — baseline testing not routine for SOF/VEL or GLE/PIB
NS5B — SofosbuvirS282T resistance: severe fitness loss — never documented clinically despite cell culture evidence; sofosbuvir is uniquely durable precisely because natural selection prevents this mutation
NS3 protease RASs: more clinically relevant with first-generation genotype-specific agents; pangenotypic agents (glecaprevir, voxilaprevir) largely overcome them

Pandemic Preparedness — The Resistance Principle

Stockpile mechanistically diverse agents: a pathogen resistant to a protease inhibitor must face a polymerase inhibitor; resistance to the polymerase inhibitor must face an entry inhibitor or a capsid inhibitor targeting a distinct step. No single agent or mechanism can anchor a pandemic response because selection pressure against any single target drives resistance to dominance — diversity of mechanism is the structural principle behind durable antiviral therapy.

Build resistance surveillance infrastructure before the outbreak, not after: establish validated resistance assays and establish baseline susceptibility distributions before widespread drug deployment. Fitness cost determines whether resistance stays at the individual patient level or spreads through untreated populations — monitor transmission networks, not just treatment failure rates, because low-fitness-cost mutations spread regardless of drug pressure.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 49: Antiviral Agents	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 56: Antiviral Agents (Non-Retroviral)	McGraw-Hill; 2023
Domingo E, Holland JJ	RNA virus mutations and fitness for survival	Annu Rev Microbiol. 1997
Coffin JM	HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy	Science. 1995
Kuritzkes DR	HIV-1 antiretroviral drug resistance	J Infect Dis. 2011
Rhee SY et al.	Human immunodeficiency virus reverse transcriptase and protease sequence database	Nucleic Acids Res. 2003
Hammer SM et al.	Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel	JAMA. 2008
Lok AS et al.	Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management	Hepatology. 2007
Pawlotsky JM	Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens	Gastroenterology. 2016
Chou S	Approach to drug-resistant cytomegalovirus in transplant recipients	Curr Opin Infect Dis. 2015
Hurt AC	The epidemiology and spread of drug resistant human influenza viruses	Curr Opin Virol. 2014
Gupta RK et al.	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries	Lancet Infect Dis. 2018
Owen DR et al.	An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19	Science. 2021